NCT02490982View on ClinicalTrials.gov

Teriflunomide Observational Effectiveness Study

CompletedOBSERVATIONAL
Enrollment

106

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

December 31, 2018

Study Completion Date

June 28, 2021

Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
DRUG

Teriflunomide

The prescription of Teriflunomide administered orally as a 14mg daily compound to RRMS patients.

Trial Locations (1)

H2L 4M1

CHUM, Montreal

All Listed Sponsors
collaborator

Genzyme, a Sanofi Company

INDUSTRY

collaborator

Montreal Neurological Institute and Hospital

OTHER

lead

Centre hospitalier de l'Université de Montréal (CHUM)

OTHER

NCT02490982 - Teriflunomide Observational Effectiveness Study | Biotech Hunter | Biotech Hunter